Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation-Reference-Cited by-同舟云学术

Outcomes of Adults with Acute Lymphoblastic Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

Published:2013-07 Issue:7 Volume:19 Page:1059-1064
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Poon Li Mei,Hamdi Amir,Saliba Rima,Rondon Gabriela,Ledesma Celina,Kendrick Monique,Qazilbash Muzaffar,Hosing Chitra,Jones Roy B.,Popat Uday R.,Nieto Yago,Alousi Amin,Ciurea Stefan,Shpall Elizabeth J.,Champlin Richard E.,Kebriaei Partow

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference25 articles.

1. Outcome of 40 adults aged from 18 to 55 years with acute lymphoblastic leukemia treated with double-delayed intensification pediatric protocol;Haïat;Leuk Res,2011

2. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia;DeAngelo;ASH Annual Meet Abstr,2007

3. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia;Bruggemann;Blood,2006

4. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL);Bassan;Blood,2009

5. Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A phase 2 study;Kantarjian;Lancet Oncol,2012

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia;Blood Advances;2024-03-13

2. Incidence and outcome of central nervous system relapse after hematopoietic stem cell transplantation in patients suffering from acute myeloid leukemia and acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Haematologica;2024-03-07

3. Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors;eJHaem;2024-02

4. Pretransplant hepatomegaly is linked to relapse in patients with leukemia and myelodysplastic syndrome not in remission;International Journal of Hematology;2024-01-22

5. Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale propensity score-based study;2024-01-17